4P59

HER3 extracellular domain in complex with Fab fragment of MOR09825


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.4 Å
  • R-Value Free: 0.250 
  • R-Value Work: 0.184 

wwPDB Validation 3D Report Full Report


This is version 1.4 of the entry. See complete history

Literature

An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin.

Garner, A.P.Bialucha, C.U.Sprague, E.R.Garrett, J.T.Sheng, Q.Li, S.Sineshchekova, O.Saxena, P.Sutton, C.R.Chen, D.Chen, Y.Wang, H.Liang, J.Das, R.Mosher, R.Gu, J.Huang, A.Haubst, N.Zehetmeier, C.Haberl, M.Elis, W.Kunz, C.Heidt, A.B.Herlihy, K.Murtie, J.Schuller, A.Arteaga, C.L.Sellers, W.R.Ettenberg, S.A.

(2013) Cancer Res. 73: 6024-6035

  • DOI: 10.1158/0008-5472.CAN-13-1198

  • PubMed Abstract: 
  • HER2/HER3 dimerization resulting from overexpression of HER2 or neuregulin (NRG1) in cancer leads to HER3-mediated oncogenic activation of phosphoinositide 3-kinase (PI3K) signaling. Although ligand-blocking HER3 antibodies inhibit NRG1-driven tumor ...

    HER2/HER3 dimerization resulting from overexpression of HER2 or neuregulin (NRG1) in cancer leads to HER3-mediated oncogenic activation of phosphoinositide 3-kinase (PI3K) signaling. Although ligand-blocking HER3 antibodies inhibit NRG1-driven tumor growth, they are ineffective against HER2-driven tumor growth because HER2 activates HER3 in a ligand-independent manner. In this study, we describe a novel HER3 monoclonal antibody (LJM716) that can neutralize multiple modes of HER3 activation, making it a superior candidate for clinical translation as a therapeutic candidate. LJM716 was a potent inhibitor of HER3/AKT phosphorylation and proliferation in HER2-amplified and NRG1-expressing cancer cells, and it displayed single-agent efficacy in tumor xenograft models. Combining LJM716 with agents that target HER2 or EGFR produced synergistic antitumor activity in vitro and in vivo. In particular, combining LJM716 with trastuzumab produced a more potent inhibition of signaling and cell proliferation than trastuzumab/pertuzumab combinations with similar activity in vivo. To elucidate its mechanism of action, we solved the structure of LJM716 bound to HER3, finding that LJM716 bound to an epitope, within domains 2 and 4, that traps HER3 in an inactive conformation. Taken together, our findings establish that LJM716 possesses a novel mechanism of action that, in combination with HER2- or EGFR-targeted agents, may leverage their clinical efficacy in ErbB-driven cancers.


    Organizational Affiliation

    Authors' Affiliations: Novartis Institutes for Biomedical Research, Cambridge, Massachusetts; Departments of Medicine and Cancer Biology; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee; MorphoSys AG, Martinsried, Germany; and Genomics Institute of the Novartis Research Foundation, San Diego, California.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Receptor tyrosine-protein kinase erbB-3
A
627Homo sapiensGene Names: ERBB3 (HER3)
EC: 2.7.10.1
Find proteins for P21860 (Homo sapiens)
Go to Gene View: ERBB3
Go to UniProtKB:  P21860
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
MOR09825 Fab fragment heavy chain
H
238N/A
Protein Feature View is not available: No corresponding UniProt sequence found.
Entity ID: 3
MoleculeChainsSequence LengthOrganismDetails
MOR09825 Fab fragment light chain
L
214N/A
Protein Feature View is not available: No corresponding UniProt sequence found.
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
NAG
Query on NAG

Download SDF File 
Download CCD File 
A
N-ACETYL-D-GLUCOSAMINE
C8 H15 N O6
OVRNDRQMDRJTHS-FMDGEEDCSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.4 Å
  • R-Value Free: 0.250 
  • R-Value Work: 0.184 
  • Space Group: I 2 2 2
Unit Cell:
Length (Å)Angle (°)
a = 124.226α = 90.00
b = 140.939β = 90.00
c = 180.247γ = 90.00
Software Package:
Software NamePurpose
PDB_EXTRACTdata extraction
BUSTERrefinement
BUSTER-TNTrefinement

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2014-03-15 
  • Released Date: 2014-04-16 
  • Deposition Author(s): Sprague, E.R.

Revision History 

  • Version 1.0: 2014-04-16
    Type: Initial release
  • Version 1.1: 2014-07-30
    Type: Database references
  • Version 1.2: 2014-12-17
    Type: Database references
  • Version 1.3: 2015-02-25
    Type: Derived calculations
  • Version 1.4: 2015-03-18
    Type: Non-polymer description